FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome

FDA has approved Joenja (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older.